Richard Struik was born in Hazerswoude in 1972. After several years working as a hospital nurse, the commercial market was getting more of his attention. Richard started his career as account manager at IPSEN. In that role he was responsible for sales of botulinum toxin on the Benelux market. After 8 years he left IPSEN and became Product Sales manager at Galderma, where he was responsible for both the aesthetic as well as the dermato-oncology market. Richard became later on business unit manager at Galderma. In this role he lead a team of product and sales managers and was P&L-responsible. He was the one achieving reimbursement by getting Metvix (PDT) on the list of expensive medicines. Finally, he lead the launch of both Azzalure (BTX) and Emmervel (HA filler) on the Dutch market. Richard has a strong network in (cosmetic-) dermatology and plastic surgery.
In 2010 he met Henk-Peter Oonk, and Cees de Bondt and started to build bo esthetics as one of the leading distributor companies in the Benelux area. After the merger of bo pharma and bo esthetics in June 2013 he became shareholder of bo medical technologies.